Predictive and prognostic value of phosphorylated c‑KIT and PDGFRA in advanced non‑small cell lung cancer harboring ALK fusion
Authors:
Open Access
- 25 January 2019
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (3) , 3071-3076
Abstract
Secondary KIT gene amplification leads to tyrosine kinase inhibitor resistance in anaplastic lymphoma kinase (ALK) fusion‑positive advanced non‑small cell lung cancer (NSCLC). The presence of the 4q12 amplicon causes the activation of downstream mast/stem cell growth factor receptor Kit (c‑Kit) or platelet‑derived growth factor receptor α (PDGFRA) signaling pathways. Therefore, in the present study, the association between the functional proteins phosphorylated c‑Kit (p‑c‑Kit) and phosphorylated PDGFRA (p‑PDGFRA) and the prognosis of ALK fusion NSCLC was investigated. Advanced stage NSCLC samples with ALK fusion were tested for their p‑c‑Kit and p‑PDGFRA content by immunohistochemical staining, and for its association with crizotinib efficacy and the survival of the patients. Of 64 eligible ALK‑positive patients with NSCLC, 30 (46.9%) were p‑c‑Kit‑positive and 10 (15.7%) were p‑PDGFRA‑positive. Brain metastases were more common in ALK‑positive cases that were p‑PDGFRA‑positive compared with those who were p‑PDGFRA‑negative. ALK‑positive patients treated with crizotinib, who exhibited high levels of p‑c‑Kit had significantly lower progression‑free survival times than those with low levels. In addition, the patients with high levels of p‑c‑Kit exhibited lower overall survival times than those with low levels. Furthermore, multivariate analysis indicated that high levels of p‑c‑Kit in patients with ALK fusion was the only significant predictive factor for crizotinib efficacy and was a prognostic factor for poor overall survival time. However, no statistically significant difference was observed in the survival of patients with different p‑PDGFRA levels. p‑PDGFRA was more frequently expressed in the ALK‑positive cases with brain metastasis. c‑Kit signaling activation may be associated with poor efficacy of crizotinib and poor prognosis in advanced ALK fusion NSCLC.Keywords
This publication has 22 references indexed in Scilit:
- Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung AdenocarcinomaJournal of Clinical Oncology, 2015
- Possible Prognostic and Therapeutic Significance of c-Kit Expression, Mast Cell Count and Microvessel Density in Renal Cell CarcinomaInternational Journal of Molecular Sciences, 2014
- Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancerOncology Letters, 2014
- The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related DiseasesInternational Journal of Biological Sciences, 2013
- Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stagesAnnals of Oncology, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- The Role of NF-E2-Related Factor 2 in Predicting Chemoresistance and Prognosis in Advanced Non–Small-Cell Lung CancerClinical Lung Cancer, 2011
- Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center populationThe Journal of Thoracic and Cardiovascular Surgery, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiformeNeuro-Oncology, 2007